Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

June 16, 2022

(From MedRhythms has entered into a license agreement with Biogen Inc. to develop and commercialize an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis. As part of the agreement, MedRhythms will receive a $3M upfront payment. MTI played a significant role in the growth and development of the Portland-based company.

Read more here.